Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's Endpoint ADAS-Cog Likely Here To Stay Despite Clinical Failures

Executive Summary

Gold standard outcome for Alzheimer's trials may have its difficulties, especially with rater error, but experts say there's no proven alternative to ADAS-cog.

Advertisement

Related Content

FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says
Looser Efficacy Standards Could Waste Taxpayer Dollars On Useless Drugs, NEJM Says
NIH Funding Boost Underscores Tensions Between Trump, Congress
Alzheon's Reclaimed Alzheimer's Drug Has Potential To Win Big – If History Doesn't Repeat
Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel